The FDA announced on 2014-12-03 that Hospira Inc. voluntarily recalled MitoXANTRONE Injection, USP due to failed stability specifications. The drug is subpotent and contains out-of-specification impurities.
How to tell if you have it
- Brand: Hospira
- Product: MitoXANTRONE Injection USP (concentrate) 2 mg/mL
- NDC: 61703-343-18, Lot Z054636AA (Expiry December 2014)
- NDC: 61703-343-65, Lot A014645AA (Expiry November 2015)
- NDC: 61703-343-66, Lot A014643AA (Expiry April 2015)
The hazard
The product failed stability specifications, resulting in subpotency and the presence of out-of-specification known and unknown impurities.
Context
GovInfoNow's records show Hospira Inc. has had 108 other recalls since 2012-04-05. Other recent recalls include a 2017-04-21 recall for hair particulates in syringes and a 2016-11-01 recall for broken ampule tips.